Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial

(2013) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy

(2012) Mattia Barbareschi et al.   VIRCHOWS ARCHIV

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

(2011) E. Razis et al.   BREAST CANCER RESEARCH AND TREATMENT

Current and emerging targeted therapies for metastatic breast cancer

(2011) Edith A. Perez et al.   CANCER

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

(2010) Toru Mukohara   CANCER SCIENCE

PI(3)King Apart PTEN's Role in Cancer

(2010) S. Zhang et al.   CLINICAL CANCER RESEARCH

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

(2010) A. Fabi et al.   ONCOLOGY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER